Chemed (CHE) Oppenheimer 35th Annual Health Care MedTech and Services Conference summary
Event summary combining transcript, slides, and related documents.
Oppenheimer 35th Annual Health Care MedTech and Services Conference summary
26 Dec, 2025Industry trends and regulatory environment
Hospice volumes and operating metrics are tracking in line with 2025 guidance, with steady performance expected to continue.
CMS has paused the special focus program for the year, with future rulemaking anticipated to benefit the industry.
Demographic shifts, especially aging baby boomers, and increased awareness of hospice benefits are driving growth.
Policy focus on earlier hospice access is expected to improve patient outcomes and generate Medicare Trust Fund savings.
Industry advocacy and a consolidated trade association have strengthened the sector’s position for the next decade.
Volume growth, admissions, and Medicare cap
Admissions trends are shifting toward more hospital-based patients, leading to shorter average stays and some compression in 2024 growth.
Sustainable long-term volume growth is projected at 8.5-9%, above historical averages, with Medicare cap as a key limiting factor.
Cap pressures in Florida are being managed by adjusting the mix of admissions and leveraging new CONs for growth.
New market entries, especially in Florida, are ramping up faster due to proactive team building and brand awareness.
New locations are expected to be accretive to Medicare cap cushion but not materially impact earnings until 2026.
Roto-Rooter business update
Roto-Rooter faced a top-line sales challenge in 2023 due to increased competition and changes in Google ad dynamics.
Management initiatives have improved sales and conversion rates, especially in commercial and water restoration segments.
Commercial business is less seasonal and is expected to drive revenue growth in 2025.
Competitive pricing pressures from private equity-backed firms are present, but the company’s brand and service model remain resilient.
Margin improvement is a focus for 2025, with ongoing adjustments to pricing and operational strategies.
Latest events from Chemed
- 2025 revenue rose 4.1%, but earnings fell; 2026 guidance anticipates stronger H2 growth.CHE
Q4 20253 Mar 2026 - Sustained EPS growth, Medicare cap management, and digital innovation drive robust 2024 results.CHE
BofA Securities 2025 Healthcare Conference2 Mar 2026 - Q2 2024 featured robust VITAS growth, Roto-Rooter declines, and raised full-year guidance.CHE
Q2 20242 Feb 2026 - Expecting high single-digit revenue and 10% EPS growth, with robust M&A and expansion plans.CHE
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - VITAS growth offset Roto-Rooter softness, driving higher revenue and raised 2024 EPS guidance.CHE
Q3 202417 Jan 2026 - VITAS posts strong growth while Roto-Rooter pivots strategy amid rising competition.CHE
UBS Global Healthcare Conference 202414 Jan 2026 - Strong hospice growth and stable margins expected, with disciplined M&A and Roto-Rooter recovery underway.CHE
Bank of America Home Care Conference11 Jan 2026 - VITAS is accelerating growth and margins, targeting 8%-10% volume gains and strategic expansion.CHE
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - VITAS drove record growth, offsetting Roto-Rooter softness; 2025 outlook remains positive.CHE
Q4 202423 Dec 2025